Evidence map›Paper›PMID 42640700›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Targeting Runx1 Slows Cyst Growth in Autosomal Dominant Polycystic Kidney Disease.

Yueyue Zhang, Chang Liu, Junchi Liu, Linda Xiaoyan Li, Vicente Torres, Xiaogang Li, Julie Xia Zhou

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yueyue ZhangDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Chang LiuDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Junchi LiuDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Linda Xiaoyan LiDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Vicente TorresDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Xiaogang LiDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-8135-342X
Julie Xia ZhouDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Funding

The crosstalk of DNA and lysine methyltransferases in ADPKD.R01DK126662 · NIDDK · MAYO CLINIC ROCHESTER · PI Xiaogang Li · 2020 to 2026
$3.0M
ADPKD: Understanding immunosuppression mechanisms and discovering treatmentR01DK129241 · NIDDK · MAYO CLINIC ROCHESTER · PI LI, XIAOGANG · 2021 to 2024
$1.8M
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK126662HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK129241NIDDK NIH HHS R01 DK126662NIDDK NIH HHS R01 DK129241
6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), the most prevalent hereditary kidney disorder, is characterized by the progressive formation and expansion of kidney cysts that ultimately destroy normal renal parenchyma. Runt-related transcription factor 1 (Runx1), a highly conserved regulator of gene expression, orchestrates diverse cellular signaling pathways. Here, we identify Runx1 as a critical driver of cyst growth in ADPKD. Runx1 expression is markedly upregulated in Pkd1 mutant renal epithelial cells and kidney tissues through a cAMP-dependent mechanism. Pharmacological inhibition of Runx1 with its selective inhibitor, Ro5-3335, significantly attenuates cyst progression in both rapidly and slowly progressive Pkd1 mouse models. Mechanistically, Runx1 enhances proliferation of cyst-lining epithelial cells by activating the AKT-mTOR, MAPK, and STAT3 signaling cascades, while suppressing p53-mediated apoptosis. Moreover, Runx1 promotes macrophage infiltration and inflammatory responses via NF-κB activation and aggravates interstitial fibrosis through the TGF-β/Smad2 pathway. Collectively, these findings uncover Runx1 as a pivotal regulator of cystic disease progression and highlight it as a promising therapeutic target for ADPKD.

Indexed as

Core Binding Factor Alpha 2 SubunitCystsPolycystic Kidney, Autosomal DominantAnimalsApoptosisCell ProliferationEpithelial CellsHumansKidneyMiceSignal TransductionTRPP Cation ChannelsCore Binding Factor Alpha 2 SubunitRunx1 protein, mouseTRPP Cation Channels

Identifiers

PMID42640700
PMCPMC13505735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.